Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Genmab's financial outlook is bolstered by the strong performance of its leading product, DARZALEX, which reported worldwide net sales exceeding previous estimates, suggesting robust market demand and growth potential. The company ended the third quarter of 2025 with approximately $3.4 billion in cash and marketable securities, reflecting a solid balance sheet that supports its ongoing investment in a diverse pipeline of oncology therapies. With upcoming clinical data catalysts and a strong positioning in the multiple myeloma market, Genmab is well-equipped to navigate the challenges in the biotech sector and maintain its profitability.

Bears say

Genmab faces significant financial risks stemming from the slowing sales of its leading product, Darzalex, along with potential setbacks in expanding its label and negative trial outcomes for other key products, particularly Epcoritamab. In a recent trial, Epcoritamab failed to meet primary endpoint efficacy criteria, prompting a reduction in projected approval probabilities, which could adversely affect future revenue streams. Additionally, the company is exposed to macroeconomic factors and dilution risks that may further impact its financial stability and market position.

GMAB has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Strong Buy based on their latest research and market trends.

According to 4 analysts, GMAB has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.